Daily non-political popular news in brief.

Five-year study by OHSU Cancer Institute shows Gleevec's excellent survival rate

Today, after five years, the overall survival of 553 subjects randomized to receive Gleevec as their initial therapy is nearly 90 percent, 95 percent if only deaths related to CML are considered. Just 5 percent of subjects discontinued Gleevec because of side effects. The results are published in the Dec. 7 issue of the New England Journal of Medicine.

Read more »

Keywords: five-year, study, ohsu, cancer, institute, shows, gleevec, excellent, survival, rate, five, year, show

« Previous | Next »

Similar news on "Five-year study by OHSU Cancer Institute shows Gleevec's excellent survival rate":

1. Gene thought to assist chemo may help cancer thrive
   05-15-2007 · EurekAlert!
   A gene thought to be essential in helping chemotherapy kill cancer cells, may actually help them thrive. In a new study of chemo patients, scientists at Georgia Tech and the Ovarian Cancer Institute found that 70 percent of subjects whose tumors had mutations in the gene p53 were still alive after five years. Patients with normal p53 displayed only a 30 percent survival rate.
   Similar news · Read more »
   
2. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
   06-02-2007 · EurekAlert!
   The study showed that sipuleucel-T did not significantly delay the time it took for a patient's PSA to reach a value of 3 ng/ml, the primary endpoint of the study, but it did show a prolongation in prostate-specific antigen doubling time (PSADT).
   Similar news · Read more »
   
3. 5-year study shows Gleevec's potency against chronic myeloid leukemia
   12-06-2006 · EurekAlert!
   In a study of patients with chronic myeloid leukemia, some 95 percent have survived the cancer after five years due to treatment with Gleevec, according to results published this week in the New England Journal of Medicine. Howard Hughes Medical Institute investigator Brian Druker, who led the five-year study, said the findings demonstrate Gleevec's effectiveness against the formerly fatal disease.
   Similar news · Read more »
   
4. OHSU Cancer Institute, 1 of largest in GIST study and Gleevec
   04-12-2007 · EurekAlert!
   Gleevec, a pill developed in conjunction with Oregon Health & Science University is again showing excellent results in preventing cancer recurrence in GIST patients after complete removal of their tumors.
   Similar news · Read more »
   
5. Study identifies women with breast cancer most likely to benefit from aromatase inhibitor
   10-23-2006 · EurekAlert!
   While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual. Tthe study's authors say potential improvement in cancer-free survival beyond five years with the added therapy may be less than two percent for most patients.
   Similar news · Read more »
   
6. High PSA velocity linked with low survival rates
   10-31-2006 · EurekAlert!
   The rate at which prostate-specific antigen levels change may help identify men with life-threatening prostate cancer, according to a study in the November 1 issue of the Journal of the National Cancer Institute.
   Similar news · Read more »
   
7. Combining therapies can improve survival for early-stage breast cancer patients
   04-03-2007 · EurekAlert!
   Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression -- treatment to stop the ovaries from functioning -- did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.
   Similar news · Read more »
   
8. OHSU researchers: Surgery, radiation gives early survival advantage in bile duct cancer
   10-28-2007 · EurekAlert!
   Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer. "Surgery and radiotherapy shows an early response benefit. It shows that the addition of radiation is potentially reasonable for the first-line treatment," said Clifton David Fuller, M.D., Ph.D., principal investigator of the study.
   Similar news · Read more »
   
9. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
   09-25-2007 · EurekAlert!
   New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with hormone-resistant prostate cancer, could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo.
   Similar news · Read more »
   
10. Study shows endemic cholera can be controlled with oral vaccines
    11-26-2007 · EurekAlert!
    Endemic cholera, a potentially fatal diarrheal disease found in the world's most impoverished countries, could be effectively controlled by orally vaccinating half of the affected populations once every two years for only pennies per dose, according to new findings by an international team of researchers led by Ira M. Longini Jr., Ph.D., a biostatistician in the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center in Seattle.
    Similar news · Read more »